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Liver receptor homolog 1 (LRH-1), an established regulator of cholesterol and bile acid homeostasis, has 
recently emerged as a potential drug target for liver disease. Although LRH-1 activation may protect the liver 
against diet-induced steatosis and insulin resistance, little is known about how LRH-1 controls hepatic glu-
cose and fatty acid metabolism under physiological conditions. We therefore assessed the role of LRH-1 in 
hepatic intermediary metabolism. In mice with conditional deletion of Lrh1 in liver, analysis of hepatic glucose 
fluxes revealed reduced glucokinase (GCK) and glycogen synthase fluxes as compared with those of wild-type 
littermates. These changes were attributed to direct transcriptional regulation of Gck by LRH-1. Impaired 
glucokinase-mediated glucose phosphorylation in LRH-1–deficient livers was also associated with reduced 
glycogen synthesis, glycolysis, and de novo lipogenesis in response to acute and prolonged glucose exposure. 
Accordingly, hepatic carbohydrate response element-binding protein activity was reduced in these animals. 
Cumulatively, these data identify LRH-1 as a key regulatory component of the hepatic glucose-sensing system 
required for proper integration of postprandial glucose and lipid metabolism.
Introduction
The liver plays a central role in metabolic homeostasis by coor-
dinating the synthesis, storage, breakdown, and redistribution 
of nutrients. Adequate control of these metabolic processes is 
of importance to accommodate systemic fuel requirements and 
availability. This is achieved through regulatory complexes that 
modulate both the catalytic activity and the expression level of 
metabolic enzymes. While the first usually enables rapid changes 
in enzymatic activity triggered by allosteric regulation or cova-
lent modification, the second regulatory process is slower and 
involves transcription factors that adjust gene expression levels. 
In this context, nuclear receptors and their coregulators have been 
shown to play a key role in the transcriptional regulation of meta-
bolic enzyme expression in response to changes in cellular nutri-
ent and energy status (1, 2).
Liver receptor homolog 1 (LRH-1, also known as NR5A2), a 
member of the NR5A superfamily of nuclear receptors, is highly 
expressed in the liver. Hepatic LRH-1 promotes the expression 
of the bile acid–synthesizing enzymes Cyp7a1 and Cyp8b1 (3–5), 
while it suppresses acute phase response genes (6, 7). As a con-
sequence, bile acid metabolism is altered in liver-specific LRH-1 
knockout mice (3, 4), and LRH-1 heterozygous animals show an 
exacerbated inflammatory response (6). Other established LRH-1 
target genes in the liver are known mediators of hepatic choles-
terol uptake and efflux (8, 9), HDL formation (10, 11), choles-
terol exchange between lipoproteins (12), and fatty acid synthesis 
(13). Although these findings point to a broader role for LRH-1 in 
hepatic lipid metabolism and reverse cholesterol transport, their 
physiological impact is as yet unknown.
Independent studies have demonstrated that human LRH-1 can 
bind several phospholipid species, including phosphoinositides 
(14–17). Interestingly, dilauroyl phosphatidylcholine (DLPC), 
which has been identified as a ligand for both mouse and human 
LRH-1 in vitro, was recently shown to confer LRH-1–dependent 
protection against hepatic steatosis and insulin resistance in mice 
exposed to chronic high-fat feeding (18). While these observations 
suggest that hepatic LRH-1 may contribute to metabolic control, 
the role of LRH-1 in hepatic glucose metabolism remains largely 
unexplored. However, insights into the mechanisms by which 
LRH-1 impacts on glucose and fatty acid metabolism in the liver 
are required for the development of therapeutic strategies to pre-
vent or treat hepatic steatosis.
In this study, we assessed the physiological role of LRH-1 in 
hepatic intermediary metabolism. We show that LRH-1 controls 
the first step of hepatic glucose uptake through direct transcrip-
tional regulation of the glucokinase (Gck) gene. As a result, mice 
lacking LRH-1 in hepatocytes fail to adequately induce glucose-
driven glycolysis, glycogen synthesis, and fatty acid synthesis in the 
liver. Altogether, our work identifies LRH-1 as a critical regulatory 
component of the glucose-sensing system that integrates hepatic 
postprandial glucose and lipid metabolism.
Results
Reduced glucokinase and glycogen synthase fluxes in Alb-Cre;Lrh1fl/fl mice. 
To explore the putative involvement of LRH-1 in intermediary 
metabolism in the liver, we quantified hepatic glucose fluxes upon 
stable isotope infusion in mice with a somatic deletion of LRH-1 
in hepatocytes (Alb-Cre;Lrh1fl/fl mice; ref. 3) and their wild-type lit-
termates (Lrh1fl/fl mice) (Figure 1A; ref. 19). Blood glucose concen-
trations were similar in Lrh1fl/fl and Alb-Cre;Lrh1fl/fl mice under both 
normoglycemic and clamped hyperglycemic conditions (Table 1). 
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Alb-Cre;Lrh1fl/fl mice showed significant reductions in the flux 
through glucokinase under both normoglycemic and hyperglyce-
mic conditions (Figure 1B). In contrast, the glucose-6-phosphatase 
flux remained unaltered (Figure 1C), resulting in increased net 
glucose flux to the blood in Alb-Cre;Lrh1fl/fl mice (Figure 1D).
Hepatic LRH-1 deficiency also affected the conversion of 
glucose-6-phosphate (G6P) into glycogen. Normoglycemic and 
hyperglycemic glycogen synthase fluxes were lowered in Alb-
Cre;Lrh1fl/fl mice (Figure 1E), while glycogen phosphorylase flux-
es remained unchanged (Figure 1F). As a consequence, hepatic 
glycogen balances were markedly reduced in Alb-Cre;Lrh1fl/fl mice 
under both conditions (Figure 1G). Overall, hepatic ablation of 
LRH-1 reduced glucose phosphorylation via glucokinase and 
impaired the capacity of the liver to con-
vert G6P into glycogen. Of interest, the 
whole-body glucose clearance rate was 
increased in Alb-Cre;Lrh1fl/fl mice under 
hyperglycemic conditions, presumably as 
a consequence of elevated insulin levels 
(Table 1). Alb-Cre;Lrh1fl/fl mice therefore 
required higher glucose infusion rates 
to maintain hyperglycemic states simi-
lar to those of their wild-type littermates 
(Table 1). However, these changes did not 
impact systemic energy metabolism. Alb-
Cre;Lrh1fl/fl mice showed normal lean and 
fat masses, and food and water intake 
was unchanged compared with that of Lrh1fl/fl mice (Supplemen-
tal Figure 1, A and B; supplemental material available online with 
this article; doi:10.1172/JCI62368DS1). Energy expenditure and 
substrate utilization were also similar to those of wild-type con-
trols (Supplemental Figure 1, C and D).
Glucokinase is a transcriptional target of LRH-1. To establish the 
basis of the reduced glucose fluxes, we evaluated the acute hepatic 
response to a glucose bolus in Lrh1fl/fl and Alb-Cre;Lrh1fl/fl mice. Glu-
cose and insulin levels showed the expected increases (Figure 2, A 
and B) and were not affected in Alb-Cre;Lrh1fl/fl mice. The expression 
of Lrh1 and its established target and corepressor SHP (20) was 
undetectable in Alb-Cre;Lrh1fl/fl mice (Figure 2C). Interestingly, 
the mRNA level of Gck, but not Hk1, was consistently reduced 
in the livers of Alb-Cre;Lrh1fl/fl mice, and its glucose-mediated 
increase was markedly blunted as compared with that in Lrh1fl/fl 
mice (Figure 2D). To evaluate whether the impaired induction 
of Gck in response to acute glucose availability also occurred 
upon prolonged glucose exposure, Lrh1fl/fl and Alb-Cre;Lrh1fl/fl 
mice were analyzed under fed, fasted, and refed conditions. Cir-
culating glucose and insulin levels were similar between geno-
types in the fed and fasted states but significantly increased in 
refed Alb-Cre;Lrh1fl/fl mice (Table 2). This was associated with 
lower pancreatic insulin content (Supplemental Figure 2), sug-
gesting compensatory pancreatic insulin release as a result of 
impaired GCK-mediated hepatic glucose uptake in refed Alb-
Cre;Lrh1fl/fl mice. As with Lrh1 and its targets Shp and Cyp8b1 (Fig-
ure 2E), the hepatic mRNA levels of Gck were robustly reduced 
in Alb-Cre;Lrh1fl/fl mice in all nutritional states (Figure 2F). Hk1 
expression remained unaffected by genotype or nutritional sta-
tus (Figure 2F). Transient transfection assays revealed that LRH-1 
contributes to basal Gck transcription irrespective of glucose 
Figure 1
Reduced hepatic glucokinase and glycogen synthase fluxes in Alb-
Cre;Lrh1fl/fl mice. (A) Schematic representation of the model used for 
mass isotopomer distribution analysis. GP, glycogen phosphorylase; 
GS, glycogen synthase; G6Pase, glucose-6-phosphatase. (B–D) 
Glucose fluxes in Lrh1fl/fl mice (white bars) and Alb-Cre;Lrh1fl/fl mice 
(black bars) under normoglycemic (NG) and hyperglycemic (HG) con-
ditions. (B) Glucokinase and (C) glucose-6-phosphatase flux and (D) 
glucose balance. (E–G) Glycogen fluxes in Alb-Cre;Lrh1fl/fl and Lrh1fl/fl 
mice under normoglycemic and hyperglycemic conditions. (E) Gly-
cogen synthase and (F) glycogen phosphorylase flux and (G) glyco-
gen balance. Data represent mean ± SEM for n = 5–9 per genotype. 
*P < 0.05 Alb-Cre;Lrh1fl/fl versus Lrh1fl/fl; #P < 0.05 hyperglycemic ver-
sus normoglycemic.
Table 1
Metabolic parameters during stable isotope infusion in Lrh1fl/fl and Alb-Cre;Lrh1fl/fl mice
 Normoglycemic  Hyperglycemic
 Lrh1fl/fl Alb-Cre;Lrh1fl/fl Lrh1fl/fl Alb-Cre;Lrh1fl/fl
Blood glucose (mmol/l) 7.2 ± 0.3 7.4 ± 0.3 17.0 ± 0.9A 15.9 ± 0.7A
Glucose clearance rate (ml/kg/min) 10.2 ± 0.5 11.5 ± 0.8 15.4 ± 0.9A 19.9 ± 1.7A,B
Plasma insulin (ng/ml) ND ND 0.2 ± 0.0 0.4 ± 0.1B
Glucose infusion rate (μmol/kg/min) 4 ± 0 4 ± 0 258 ± 16A 319 ± 45A
ND, not determined. Data represent mean ± SEM for n = 5–9. AP < 0.05 versus normoglycemic;  
BP < 0.05 versus Lrh1fl/fl.
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availability, since activation of a heterologous and an endogenous 
LRH-1 reporter construct by LRH-1 was similar under low (5 mM) 
and high (25 mM) levels of glucose (Figure 2G).
We then evaluated whether glucokinase is subject to direct tran-
scriptional control by LRH-1. Since Lrh1 and Shp expression was 
abolished in the livers of Alb-Cre;Lrh1fl/fl mice (Figure 2, C and E), 
we first assessed whether changes in Gck mRNA levels arise from 
altered LRH-1 or SHP activity by means of adeno-associated viral 
vector-serotype 8–mediated (AAV8-mediated) SHP reconstitu-
tion in Alb-Cre;Lrh1fl/fl mice. Consistent with the lower expression 
of LRH-1 targets Cyp8b1 and Srb1, SHP reconstitution also did 
not normalize the expression of Gck (Figure 3A). Reduced Gck 
mRNA levels in Alb-Cre;Lrh1fl/fl mice translated into lower GCK 
protein expression (Figure 3B). The LRH-1–mediated control of 
Gck expression was also confirmed in vitro. In line with reduced 
Gck mRNA levels in the absence of LRH-1, adenoviral overexpres-
sion of LRH-1 in mouse primary hepatocytes markedly induced 
Lrh1, Shp, Cyp8b1, and Gck expression (Figure 3C). Moreover, Shp 
and Gck mRNA levels were robustly elevated in mouse hepatoma 
cells that overexpressed LRH-1 (Figure 3D), resulting in enhanced 
glucose uptake and phosphorylation (Figure 3E). Computational 
analysis revealed 6 putative LRH-1 binding sites in the mouse Gck 
promoter (Figure 3F), and ChIP analysis of hepatic DNA from 
Lrh1fl/fl and Alb-Cre;Lrh1fl/fl mice identified specific recruitment of 
LRH-1 to sites 5 and 6, which are most proximal to the transcrip-
tion initiation site in the hepatic Gck promoter (ref. 21; Figure 3, 
F and G). Site-directed mutagenesis of these sites identified site 
6 downstream from the transcription initiation site as the major 
functional site that confers LRH-1 responsiveness (Figure 3H).
Reduced glycogen synthesis, glycolysis, de novo lipogenesis, and Chrebp 
activity in Alb-Cre;Lrh1fl/fl mice. Perturbed glucokinase activity 
impacts on hepatic glucose and lipid metabolism (22, 23). We 
Figure 2
Reduced glucokinase expression in Alb-Cre;Lrh1fl/fl mice. (A) Blood glucose and (B) plasma insulin concentrations (n = 10 per genotype) and 
(C and D) hepatic mRNA levels of Lrh1, Shp, Gck, and Hk1 during an oral glucose tolerance test (n = 4–8 per genotype) in Lrh1fl/fl mice (white 
boxes) and Alb-Cre;Lrh1fl/fl mice (black boxes). (E and F) Hepatic mRNA levels in fed, 24-hour–fasted or 6-hour–refed Lrh1fl/fl mice (white bars) 
and Alb-Cre;Lrh1fl/fl mice (black bars) (n = 7–9 per genotype). (G) LRH-1 transcriptional activity in HeLa cells transfected with a heterologous (4x 
LRH-1 response element–Luc [4xLRE-Luc]) or an endogenous LRH-1 reporter driven by the Shp promoter (SHP-Luc). Luciferase activity was 
determined in the absence (empty; white bars) or presence (LRH-1; black bars) of LRH-1 after exposure to 5 or 25 mM glucose for 24 hours. 
Data are expressed as relative light units (RLUs) compared with empty reporter (pGL3). Data represent mean ± SEM. *P < 0.05 versus Lrh1fl/fl 
or versus empty vector (pCMX).
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hypothesized that hepatic ablation of LRH-1 would limit the 
availability of G6P for glycogen synthesis, glycolysis, and de novo 
lipogenesis. We therefore analyzed these biochemical pathways 
downstream of glucokinase in Alb-Cre;Lrh1fl/fl mice. In accordance 
with the reduction in the flux to glycogen (Figure 1, E and G), 
we observed that the accumulation of hepatic glycogen, which 
usually occurs within 30 minutes after an oral glucose bolus 
in Lrh1fl/fl mice, was markedly delayed in Alb-Cre;Lrh1fl/fl mice, in 
which glycogen levels were maximally increased after only 1 hour 
(Figure 4, A and B). In addition to this acute effect, glycogen con-
tent was also significantly lower in the livers of fed and refed Alb-
Cre;Lrh1fl/fl mice (Figure 4C). In parallel to the reduced glucokinase 
flux in Alb-Cre;Lrh1fl/fl mice, we observed that primary hepatocytes 
from Alb-Cre;Lrh1fl/fl mice exhibited lower extracellular acidification 
rates when exposed to glucose, which is indicative of reduced gly-
colysis (Figure 4D). Besides its role in ATP generation, glycolysis 
also provides substrates for de novo fatty acid synthesis. Corre-
spondingly, we found that gene expression of lipogenic enzymes 
was reduced in Alb-Cre;Lrh1fl/fl mice (Figure 5A). The induction of 
Acaca expression upon refeeding was attenuated in Alb-Cre;Lrh1fl/fl 
mice, while Fasn and Scd1 mRNA levels were lower in all condi-
tions studied (Figure 5A). Acacb expression was also reduced in 
refed Alb-Cre;Lrh1fl/fl mice (Figure 5A). To unequivocally establish 
the physiological relevance of these findings, we used 13C-acetate 
to enrich the acetyl-CoA pool and quantified fractional de novo 
palmitate, stearate, and oleate synthesis rates (Figure 5B). Con-
sistent with the reduction in glycolysis, de novo lipogenesis was 
reduced in fed and refed Alb-Cre;Lrh1fl/fl mice as compared with 
that in wild-type littermates (Figure 5B). Accordingly, plasma 
triglyceride concentrations were decreased in fed and refed Alb-
Cre;Lrh1fl/fl mice compared with those in Lrh1fl/fl mice (Table 2).
Previous work has shown that hepatic GCK ablation reduces car-
bohydrate response element-binding protein (Chrebp) and pyruvate 
kinase (Pklr) expression (23). In accordance with this, and consistent 
with the observed reduction in glycolysis (Figure 4D) and de novo 
lipogenesis (Figure 5), we observed that the expression of Chrebp and 
Pklr was lower in fed and refed Alb-Cre;Lrh1fl/fl mice (Figure 6A). On 
the other hand, the mRNA levels of sterol regulatory element bind-
ing protein 1c (Srebp-1c) and its target gene glucose-6-phosphate 
dehydrogenase (G6pd1) were not changed in Alb-Cre;Lrh1fl/fl mice 
(Figure 6A). Nuclear ChREBP protein was also reduced in refed Alb-
Cre;Lrh1fl/fl mice (Figure 6B), consistent with lower hepatic G6P con-
tent under these conditions (Figure 6C; ref. 24). This was not attrib-
uted to the concomitant loss of hepatic SHP in the Alb-Cre;Lrh1fl/fl 
mice, since Shp reconstitution did not restore Chrebp and Pklr mRNA 
levels (Figure 6D). To establish whether the reduction in glycolytic 
and lipogenic gene expression in the livers of Alb-Cre;Lrh1fl/fl mice 
results from direct regulation of Chrebp transcription by LHR-1, we 
evaluated the effect of LRH-1 on Chrebp promoter activation. Unlike 
the Gck promoter (Figure 3H), LRH-1 did not directly activate the 
mouse Chrebp promoter, while a robust transactivation of the Shp 
promoter was observed in response to LRH-1 (Figure 6E), indicating 
that LRH-1 impacts ChREBP in an indirect manner.
Based on previous studies showing that GCK is required for 
optimal ChREBP expression and activity (23–25), we postulat-
ed that LRH-1 indirectly modulates ChREBP via GCK. To sup-
port this hypothesis, we rescued hepatic Gck expression in Alb-
Cre;Lrh1fl/fl mice by AAV8-mediated gene transfer (Figure 6F). 
Consistent with reduced nuclear ChREBP expression and hepatic 
G6P content (Figure 6, B and C), Pklr and Acaca mRNA levels 
were normalized in Alb-Cre;Lrh1fl/fl mice upon Gck reconstitu-
tion, indicating that the lower expression levels of these ChREBP 
target genes occurs secondary to a reduced flux through GCK 
in Alb-Cre;Lrh1fl/fl mice. Hepatic Fasn expression, on the other 
hand, remained low upon GCK reconstitution in Alb-Cre;Lrh1fl/fl 
mice, consistent with a previous study that identified this gene 
as a direct target of LRH-1 (13). Scd1 mRNA levels showed a 
dose-dependent response to Gck rescue in Alb-Cre;Lrh1fl/fl mice 
(Figure 6F). Combined, these data indicate that LRH-1 acts as an 
upstream regulator of GCK and as such indirectly impacts glyco-
lytic and, at least in part, lipogenic gene expression.
Discussion
Hepatic LRH-1 is an established transcriptional regulator of cho-
lesterol and bile acid homeostasis (3–5, 14, 26). Here, we report 
that LRH-1 directly regulates intrahepatic glucose and fatty acid 
metabolism during the postprandial phase. Our data show that 
both loss and gain of LRH-1 function control glucokinase expres-
sion and impact hepatic glucose uptake in liver and hepatocytes. 
The LRH-1–driven flux through glucokinase in turn critically 
determines the partitioning of G6P toward glycogen storage, gly-
colysis, and de novo lipogenesis. Hence, we believe that this study 
confirms the unique and essential ability of hepatic glucokinase 
to properly accommodate glucose availability to its oxidation and 
storage (22, 23, 27) and reveals a novel upstream regulator of its 
activity that determines the capacity for hepatic glucose uptake 
upon glucose exposure.
Glucokinase mediates hepatic glucose uptake and, as such, rep-
resents the first step of glucose metabolism in the liver. Its prod-
uct, G6P, is a central metabolite for intrahepatic glucose and lipid 
homeostasis. This metabolite serves as the substrate for the oxida-
tion of glucose as well as its storage as glycogen and fat. Hepatic 
glucokinase expression depends on the nutritional state and is sub-
ject to reciprocal regulation by insulin and glucagon (28). Differ-
ent transcription factors, including liver X receptor (LXR), PPARγ, 
and SREBP-1c, are known to interact to control glucokinase 
Table 2
Metabolite concentrations in fed, 24-hour–fasted, and 6-hour–refed Lrh1fl/fl and Alb-Cre;Lrh1fl/fl mice
 Fed  Fasted  Refed
 Lrh1fl/fl Alb-Cre;Lrh1fl/fl Lrh1fl/fl Alb-Cre;Lrh1fl/fl Lrh1fl/fl Alb-Cre;Lrh1fl/fl
Blood glucose (mmol/l) 7.6 ± 0.2 7.9 ± 0.3 3.9 ± 0.1A 3.5 ± 0.2A 7.6 ± 0.2B 8.4 ± 0.3B,C
Plasma insulin (ng/ml) 0.5 ± 0.1 0.5 ± 0.1 0.1 ± 0.0A 0.1 ± 0.0A 0.7 ± 0.1A,B 1.2 ± 0.2A,B,C
Plasma triglyceride (mmol/l) 1.2 ± 0.2 0.7 ± 0.1 1.1 ± 0.2 1.3 ± 0.1A 1.4 ± 0.1B 0.6 ± 0.1B,C
Data represent mean ± SEM for n = 5–9. AP < 0.05 versus fed; BP < 0.05 versus fasted; CP < 0.05 versus Lrh1fl/fl.
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expression (29). The induction of Gck in response to refeeding 
is, however, not significantly impaired in LXR- or Srebp-1c–defi-
cient mice (30–32). In this study, we observed a profound and 
consistent reduction in Gck mRNA levels in fed, fasted, and refed 
Alb-Cre;Lrh1fl/fl mice, confirming previous observations in insulin-
resistant mice (18). Together, these data suggest that LRH-1 is 
a major regulator of hepatic glucokinase expression. Metabolic 
alterations in Alb-Cre;Lrh1fl/fl mice may, however, also be related 
to lower Shp expression. This is of importance given that SHP 
acts as a transrepressor on LXRα- or PPARγ-mediated Gck induc-
tion (29). However, a recent report showed that SHP deficiency 
does not impact hepatic Gck expression in chow-fed mice (33). 
This observation is consistent with the results obtained in this 
study. By means of ChIP analysis, site-directed mutagenesis, and 
SHP reconstitution experiments, we have firmly established that 
LRH-1 directly controls Gck transcription.
LRH-1 specifically acts on glucokinase transcription, since no 
significant differences in hexokinase expression were observed 
between Lrh1fl/fl and Alb-Cre;Lrh1fl/fl mice. This is of particular inter-
est, because it has been shown that only G6P generated through 
glucokinase determines the metabolic fate of intrahepatic glucose 
(34, 35). Liver-specific glucokinase knockout mice show a reduc-
tion in glycogen synthesis under hyperglycemic conditions (22). In 
this study, we also observed reduced glycogen storage and a lower 
glycogen synthase flux in the livers of Alb-Cre;Lrh1fl/fl mice. Glu-
cokinase is furthermore required to increase Chrebp mRNA levels 
in response to refeeding and is critical for the ChREBP-mediated 
induction of glycolytic and lipogenic genes in response to glucose 
(23). Importantly, recent work has identified G6P as the actual 
metabolic signal that drives ChREBP-mediated control of glycoly-
sis and lipogenesis (24, 25). In line with this, we observed that refed 
Alb-Cre;Lrh1fl/fl mice showed reduced hepatic G6P content along 
Figure 3
Gck is a direct transcriptional target of LRH-1. (A) Hepatic mRNA levels in Alb-Cre;Lrh1fl/fl mice 5 weeks after in vivo transduction of the liver 
using AAV8-SHP virus (gray bars) in comparison with those in Lrh1fl/fl mice (white bars) and Alb-Cre;Lrh1fl/fl mice (black bars) (n = 4–5 per 
group). (B) Hepatic GCK protein expression in refed Lrh1fl/fl and Alb-Cre;Lrh1fl/fl mice. (C and D) Expression levels of LRH-1 and its targets 
in (C) wild-type primary hepatocytes and (D) Hepa 1.6 mouse hepatoma cells transduced with AdGFP (white bars) or AdLRH-1 (black bars) 
viruses (n = 3 per condition). (E) 2-deoxyglucose (2-DG) uptake and 2-deoxyglucose-6-phosphate (2-DG6P) production in Hepa 1.6 cells 
transduced with AdGFP (white bars) or AdLRH-1 (black bars) viruses (n = 6 per condition). (F) Schematic presentation of the 6 putative 
LRH-1 response elements in the mouse Gck promoter. (G) Assessment of LRH-1 recruitment to these sites, as depicted in F, determined 
by ChIP analysis using genomic DNA from livers of Lrh1fl/fl and Alb-Cre;Lrh1fl/fl mice. (H) Luciferase activities in HeLa cells transfected with 
empty luciferase reporter (pGL3; white bar) or long and short Gck promoter constructs (black bars). Data are expressed as fold induction in 
luciferase activity upon LRH-1 cotransfection. Data represent mean ± SEM. *P < 0.05 versus Lrh1fl/fl, versus GFP, or versus empty reporter 
(pGL3); #P < 0.05 versus Alb-Cre;Lrh1fl/fl.
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with a suboptimal induction of glycolytic and lipogenic genes. The 
reconstitution of hepatic SHP furthermore revealed that, similar 
to those of Gck, the lower expression levels of Chrebp and its target 
Pklr in Alb-Cre;Lrh1fl/fl mice are also caused by the absence of LRH-
1, and not SHP, in the liver. Reduced mRNA levels of Chrebp and 
its targets in Alb-Cre;Lrh1fl/fl mice were associated with lowered gly-
colytic and lipogenic fluxes as well as reduced plasma triglyceride 
levels. The reduction in glycolysis in Alb-Cre;Lrh1fl/fl mice results 
from impaired GCK activity, as Pklr expression was completely 
normalized upon hepatic Gck rescue. Gck reconstitution also 
restored the mRNA levels of the ChREBP target Acaca, but not 
the expression of Fasn, which is a direct target of both ChREBP 
and LRH-1 (13, 23). The reduced de novo lipogenesis in Alb-
Cre;Lrh1fl/fl mice therefore most likely results from a concerted 
impairment of both ChREBP-dependent and LRH-1–dependent 
lipogenesis. Thus, although the flux through glucokinase is only 
partially inhibited in Alb-Cre;Lrh1fl/fl mice, these animals present 
a striking phenotypic resemblance to liver-specific glucokinase 
knockout mice with regard to glycogen storage and ChREBP-
mediated glycolysis and lipogenesis (22, 23).
Genetic models of obesity and type 2 diabetes, including ob/ob 
and db/db mice, have been reported to display increased hepatic 
glucokinase expression and flux (36–38), along with ChREBP 
hyperactivity and hepatic steatosis, which is partially reversible by 
ChREBP inhibition (39). Importantly, glucokinase expression is 
also associated with lipogenic activity and fatty liver in humans 
(40). This implies that a reduction in LRH-1 activity would have 
a potential protective effect on steatosis development via reduced 
glucokinase-mediated ChREBP activation when hepatic glucose 
availability is high, e.g., in obese diabetic states. Although Alb-
Cre;Lrh1fl/fl mice are not protected against high-fat diet–induced 
glucose intolerance and insulin resistance (Supplemental Figure 
3 and ref. 18), it was recently shown that DLPC administration 
improves insulin sensitivity and liver steatosis in an LRH-1–depen-
dent manner (18). It was proposed that DLPC-mediated LRH-1 
activation interferes with the insulin/SREBP-1c signaling cascade 
that drives lipogenesis in the liver. In this study, we observed that 
the hepatic mRNA levels of Srebp-1c and its target G6pd1 were unal-
tered in insulin-sensitive Alb-Cre;Lrh1fl/fl mice. This is in agreement 
with a report showing that Srebp-1c and G6pd1 expression levels are 
not altered upon glucokinase overexpression, while those of the 
ChREBP targets Pklr and Acaca/Acacb are induced (41). Combined, 
current and previous findings (18) indicate that LRH-1 impacts on 
hepatic lipogenesis via alternate routes under different nutritional 
and pathophysiological conditions.
In conclusion, these data indicate that LRH-1 is a major and 
essential transcriptional regulator of glucokinase, the gatekeeper 
of hepatic glucose metabolism. As a consequence, LRH-1 not only 
controls the initial step of glucose uptake but also determines the 
intrahepatic fate of its product G6P. Our data identifies LRH-1 as 
a critical component of the hepatic glucose-sensing system that 
integrates glucose and lipid homeostasis in the postprandial phase.
Figure 4
Delayed glycogen synthesis and reduced glycolysis in Alb-Cre;Lrh1fl/fl mice. (A) Representative glycogen stainings during oral glucose tolerance 
test (n = 3–8 per genotype). Scale bar: 200 μm. (B) Quantification of hepatic glycogen content in Lrh1fl/fl mice (white boxes) and Alb-Cre;Lrh1fl/fl mice 
(black boxes) during oral glucose tolerance test. (C) Hepatic glycogen content in fed, 24-hour–fasted, or 6-hour–refed Lrh1fl/fl mice (white bars) and 
Alb-Cre;Lrh1fl/fl mice (black bars) (n = 7 per genotype). (D) Extracellular acidification rates (ECARs) in Lrh1fl/fl (white boxes) and Alb-Cre;Lrh1fl/fl (black 
boxes) primary hepatocytes (n = 5–6 per genotype). Data represent mean ± SEM. *P < 0.05 versus Lrh1fl/fl.
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Methods
For more details, see the Supplemental Methods. Unless otherwise indi-
cated, all chemical reagents were obtained from Sigma-Aldrich.
Generation of viral vectors. AAV8 encoding the mouse SHP or GCK 
cDNAs (AAV8-SHP or AAV8-GCK), driven by the hybrid cytomegalovi-
rus enhancer/chicken β-actin constitutive promoter or the liver-specific 
α1-antitrypsin promoter (hAAT; ref. 42), respectively, were generated and 
titrated as described previously to enable their use in vivo (43, 44). Plasmids 
used to generate viral particles and the hAAT promoter were provided by 
K.A. High, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, 
USA. For in vitro experiments, cells were transduced with an adenoviral 
vector encoding the mouse Lrh1 gene (AdLRH-1; derived from pCMX-
mLRH-1; ref. 8) using the Adeno-X Expression System (Clontech).
Animal studies. LRH-1 floxed mice (3) were crossed with serum albumin-
Cre mice (The Jackson Laboratory) and then further intercrossed to gen-
erate hepatocyte-specific LRH-1 knockout (Alb-Cre;Lrh1fl/fl) and wild-type 
(Lrh1fl/fl) mice on a pure C57BL/6J background. Animals had ad libitum 
access to regular chow (Teklad no. 2016, Harlan) and drinking water and 
were kept under a 12-hour-dark/12-hour-light cycle (lights on 7 AM to 7 
PM). At the end of the experiments, mice were sacrificed by cardiac punc-
ture under isoflurane anesthesia, and livers were quickly snap frozen.
For quantification of carbohydrate fluxes, mice were equipped with a 
permanent jugular vein catheter, after which they were allowed a recovery 
period of at least 3 days (45). Prior to the infusion experiment, mice were 
fasted overnight. They were infused with a solution containing [U-13C]glu-
cose, [2-13C]glycerol, [1-2H]galactose, and paracetamol at an infusion rate 
of 0.6 ml per hour, as previously described, for 210 minutes (19). Then, the 
infusion of a second solution containing glucose (1,067 mM) and [U-13C]
glucose (50 mM) was initiated, while the infusion of the first solution was 
continued. The infusion rate of the second solution was adjusted according 
to the blood glucose concentration in order to maintain comparable hyper-
glycemia in both genotypes. These infusions were prolonged for another 
210 minutes. During the entire experiment, blood glucose concentrations 
were measured and blood and urine samples were collected on filter paper 
at regular time intervals (46). After 420 minutes, mice were sacrificed.
For oral glucose tolerance tests, mice were fasted overnight and subse-
quently challenged with a glucose bolus (2 g/kg) by gavage. At regular time 
points, blood glucose concentrations were measured, and blood samples 
were collected to determine insulin levels. Separate groups of mice were 
sacrificed after 0, 30, and 60 minutes.
For fasting-refeeding experiments, fed and 24-hour–fasted mice were 
sacrificed at 7 AM. Refed mice were fasted for 24 hours, starting at 7 AM, 
and were subsequently refed with normal chow diet for 6 hours. To quan-
tify fatty acid synthesis rates, all mice received sodium[1-13C] acetate via 
their drinking water (2%) 24 hours prior to sacrifice.
For SHP reconstitution experiments, Alb-Cre;Lrh1fl/fl mice received an 
injection of SHP-AAV8 vector (1012 particles per mouse) into the jugular 
vein under isoflurane anesthesia. Five weeks after vector administration, 
the mice were sacrificed after a 6-hour fast. For GCK reconstitution experi-
ments, Alb-Cre;Lrh1fl/fl mice received an injection of GCK-AAV8 vector (1011 
or 1012 particles per mouse) into the jugular vein under isoflurane anesthe-
sia. Five weeks after vector administration, the mice were sacrificed after 
6 hours of refeeding. Hepatic gene expression levels were compared with 
those of Lrh1fl/fl and Alb-Cre;Lrh1fl/fl mouse AAV8 vector particles carrying a 
noncoding genome (AAV8-null).
Biochemical analysis. The extraction of glucose from blood and urine 
spots, the derivatization of the extracted compounds, the GC-MS analy-
sis of these derivatives, and the calculation of hepatic carbohydrate fluxes 
were performed as described previously (46, 47). Blood glucose concentra-
tions were measured using a Maxi Kit glucometer (Bayer Diagnostics). Plas-
ma insulin and triglyceride concentrations were determined using com-
mercially available ELISA (Crystal Chem Inc.) and enzymatic kits (Roche), 
respectively. Hepatic triglyceride content was quantified after lipid extrac-
tion (48) using an enzymatic assay (Roche). Fatty acids derived from these 
hepatic lipid extracts were liberated, derivatized, and subjected to GC-MS 
analysis in order to calculate fractional synthesis rates from the incorpora-
tion of 13C-acetate as described previously (49). Hepatic glycogen and G6P 
content were determined using enzymatic assays (50, 51).
Histological analysis. In order to visualize hepatic glycogen disposition, 
hematoxylin and eosin and periodic acid-Schiff stainings were performed 
on 4-μm-thick liver sections.
Cell culture. Primary hepatocytes were isolated using collagenase 
perfusion as described previously with minor modifications (23). 
Hepatocytes from Lrh1fl/fl mice were plated in DMEM 4.5 g/l glucose with 
10% FBS. Four hours after plating, cells were transduced with AdLRH-1 or 
AdGFP. Hepatocytes were then incubated in DMEM 4.5 g/l glucose with-
out serum for 36 hours and lysed for RNA isolation.
Primary hepatocytes from Alb-Cre;Lrh1fl/fl and Lrh1fl/fl mice were seeded 
in Seahorse XF24 plates (Seahorse Bioscience) containing glucose-free 
medium without serum for 24 hours. They were subsequently exposed to 
25 mM glucose, and the extracellular acidification rate (a measure of gly-
colysis) was measured at 5-minute intervals by the Seahorse XF24 system 
(Seahorse Bioscience).
Hepa 1.6 mouse hepatoma cells were cultured in DMEM 4.5 g/l glucose 
with 10% FBS, 1% NEAA, and 0.1% gentamicin. These cells were trans-
duced with AdLRH-1 or AdGFP. After 12 hours, media were changed and 
incubation was continued for another 30 hours. Then, cells were rinsed 
with PBS 3 times and either lysed in Tri Reagent (Invitrogen) for RNA iso-
lation or exposed to 2-[14C]deoxyglucose (DOG; 0.1 mCi) for 10 minutes 
to quantify DOG incorporation as described previously (52). In short, 
cells were rinsed with 0.1 mM phloretin to further inhibit sugar efflux 
Figure 5
Reduced de novo lipogenesis in Alb-Cre;Lrh1fl/fl mice. (A) Hepatic lipo-
genic gene expression and (B) de novo synthesis of hepatic palmitate, 
stearate, and oleate in fed, fasted, and refed Lrh1fl/fl mice (white bars) 
and Alb-Cre;Lrh1fl/fl mice (black bars) (n = 7–9 per genotype). Data 
represent mean ± SEM. *P < 0.05 versus Lrh1fl/fl.
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and lysed in 1 M NaOH at 60°C for 10 minutes. The lysates were neutral-
ized in 1 M HCl and centrifuged. 0.3 M ZnSO4 and 0.3 M Ba(OH)2 were 
added to the supernatant, and the mixture was centrifuged. Then, 6% 
perchloric acid was added to the supernatant. After the centrifugation, 
the radioactivity of the supernatant was measured by a liquid scintilla-
tion counter. Radioactive counts were normalized to DNA content to 
determine DOG uptake and G6P production.
Cloning and site-directed mutagenesis. A 0.6-kb fragment (–601 to +10) of the 
murine Shp promoter, as well as a long (~1.2 kb; –1,063 to +141) and short 
(~0.6 kb; –514 to +141) fragment of the murine hepatic Gck promoter (21) 
(GCK long and short), were amplified from mouse liver genomic DNA. 
These fragments were inserted into the multiple cloning site of the pGL3-
basic reporter (Promega Life Science). The heterologous LRH-1 reporter 
vector was generated by subcloning 4 repeats of an established LRH-1 
response element in the human Shp promoter (–79 to –71) into the mul-
tiple cloning site of the TK-pGL3 reporter (Promega Life Science).
Mutations in putative LRH-1 responsive elements 5 and 6 (Figure 3F) 
in the GCK short reporter were introduced using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene). Additional mutagenesis was per-
formed to obtain GCK short mutant elements 5 and 6 (mt5-6), from the 
GCK short mt5. The sequences of all reporter constructs were analyzed 
and confirmed.
Transient transfection and cell reporter assays. All transfections were per-
formed using Lipofectamin 2000 (Invitrogen). HeLa cells were transfected 
under low (5 mM) glucose conditions with reporter constructs driven by 
a heterologous promoter, consisting of 4 consensus LRH-1 response ele-
ments, or driven by the endogenous Shp promoter in the presence of either 
pCMX-mLRH-1 or pCMX-empty (8). After 6 hours, media were changed 
to either high (25 mM) or low (5 mM) glucose. Luciferase activities were 
determined 24 hours later and normalized for β-galactosidase activities. 
Luciferase activities in HeLa cells transfected with Chrebp promoter report-
er (53), the Shp promoter reporter, or the different Gck promoter reporters 
Figure 6
Impaired GCK activity in Alb-Cre;Lrh1fl/fl mice reduces ChREBP expression and activity. (A) Hepatic Chrebp, Pklr, Srebp-1c, and G6pd1 expression 
in fed, 24-hour–fasted, or 6-hour–refed Lrh1fl/fl mice (white bars) and Alb-Cre;Lrh1fl/fl mice (black bars) (n = 7–9 per genotype). (B) Nuclear ChREBP 
protein expression in 24-hour–fasted and 6-hour–refed Lrh1fl/fl and Alb-Cre;Lrh1fl/fl mice. (C) Hepatic G6P content in fasted and refed Lrh1fl/fl mice (white 
bars) and Alb-Cre;Lrh1fl/fl mice (black bars) (n = 6–7 per genotype). (D) Hepatic Chrebp and Pklr expression in Alb-Cre;Lrh1fl/fl mice 5 weeks after in 
vivo transduction of the liver using AAV8-SHP virus (gray bars) in comparison with that in Lrh1fl/fl mice (white bars) and Alb-Cre;Lrh1fl/fl mice (black bars) 
(n = 4–5 per group). (E) Luciferase activities in HeLa cells transfected with Chrebp (ChREBP-Luc) or SHP (SHP-Luc) promoter (black bars) constructs 
in the absence (empty; white bars) or presence (LRH-1; black bars) of LRH-1. Data are expressed as relative light units and normalized to empty 
reporter (pGL3). (F) Hepatic mRNA levels in Alb-Cre;Lrh1fl/fl mice 5 weeks after in vivo transduction of the liver using 2 different titers of AAV8-GCK 
virus (low, 1011 particles per mouse [light gray bars], and high, 1012 particles per mouse [dark gray bars]) in comparison with those in Lrh1fl/fl mice (white 
bars) and Alb-Cre;Lrh1fl/fl mice (black bars) (n = 4–5 per group). Data represent mean ± SEM. *P < 0.05 versus Lrh1fl/fl or versus empty vector (pCMX); 
#P < 0.05 versus Alb-Cre;Lrh1fl/fl.
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Office (Vaud, Switzerland) and the local committee for animal experimen-
tation (license no. 2331; Ecole Polytechnique Fédérale de Lausanne).
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in normal culture conditions (25 mM glucose) in the presence of either 
pCMX-mLRH-1 or pCMX-empty were determined 30 hours after transfec-
tion and normalized for β-galactosidase activities. All experiments were 
performed 3 times, and data represent average values of a representative 
experiment, which was performed in quadruplicate and normalized for 
empty luciferase reporter (pGL3) activity.
Quantitative RT-PCR and ChIP. RNA was isolated from liver samples and 
cells using Tri Reagent, and quantitative RT-PCR was performed as described 
previously (3). Primer sequences are listed in Supplemental Table 1. 
Gene expression levels were normalized for β2 microglobulin.
ChIP analysis was performed as described previously with minor adap-
tations (54). DNA was purified using the PCR clean-up Gel extraction Kit 
(Macherey-Nagel), after which qPCR was performed as described previous-
ly (3). Data were normalized for GAPDH promoter binding and expressed 
relative to IgG. ChIP primer sequences are listed in Supplemental Table 1.
Western blot analysis. Total liver and nuclear protein extracts were prepared, 
and lysates were subjected to Western blotting as described previously (3). 
Blots were probed with GCK (55), ChREBP (Novus), LRH-1 (56), Parp-1 (Santa 
Cruz Biotechnology Inc.), and HSP90 (BD Transduction Laboratories).
Statistics. Data are presented as mean ± SEM. Statistical significance 
(P < 0.05) was assessed using the Kruskal-Wallis test followed by the 
Conover test for post-hoc analysis.
Study approval. All animal studies were performed in accordance with 
Swiss animal protection law and were approved by the Cantonal Veterinary 
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